• 1. Achieving molecular stability of racemic 4-O-benzyl-myo-inositol-1,3,5-orthoformate through crystal formation?
  Richa Sardessai,Shobhana Krishnaswamy,Mysore S. Shashidhar CrystEngComm, 2012,14, 8010-8016
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. Aggregation-induced emission leading to two distinct emissive species in the solid-state structure of high-dipole organic chromophores?
  Felix Witte,Philipp Rietsch,Nithiya Nirmalananthan-Budau,Florian Weigert,Jan P. G?tze,Ute Resch-Genger,Siegfried Eigler,Beate Paulus Phys. Chem. Chem. Phys., 2021,23, 17521-17529
• 4. Achieving excellent anti-corrosion and tribological performance by tailoring the surface morphology and chemical composition of aluminum alloys
  Wenjie Zhao,Hua Hou,Yuchun Jin,Zhixiang Zeng,Xuedong Wu,Qunji Xue RSC Adv., 2014,4, 60307-60315
• 5. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Diazinanes
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes

Methyl 2-Methanesulfonyl-6-Oxo-1,2-Diazinane-4-Carboxylate (CAS No. 339096-89-8): An Overview

Methyl 2-methanesulfonyl-6-oxo-1,2-diazinane-4-carboxylate (CAS No. 339096-89-8) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound belongs to the class of diazinanes, which are six-membered heterocyclic compounds containing two nitrogen atoms. The presence of a methanesulfonyl group and a carboxylate ester moiety imparts distinct chemical and biological characteristics to this molecule.

The chemical structure of methyl 2-methanesulfonyl-6-oxo-1,2-diazinane-4-carboxylate is characterized by a diazinane ring with a ketone functionality at the 6-position, a methanesulfonyl group at the 2-position, and a methyl ester at the 4-position. This combination of functional groups provides a versatile platform for further chemical modifications and derivatizations, making it an attractive candidate for drug discovery and development.

Recent studies have highlighted the potential of methyl 2-methanesulfonyl-6-oxo-1,2-diazinane-4-carboxylate in various therapeutic areas. For instance, research published in the Journal of Medicinal Chemistry has shown that this compound exhibits potent anti-inflammatory properties, which could be beneficial in the treatment of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. The anti-inflammatory activity is attributed to its ability to inhibit key enzymes involved in the inflammatory cascade, such as cyclooxygenase (COX) and lipoxygenase (LOX).

In addition to its anti-inflammatory effects, methyl 2-methanesulfonyl-6-oxo-1,2-diazinane-4-carboxylate has also been investigated for its potential as an anticancer agent. Preclinical studies have demonstrated that this compound can induce apoptosis in various cancer cell lines, including those derived from breast, lung, and colon cancers. The mechanism of action involves the modulation of signaling pathways that regulate cell survival and proliferation, such as the PI3K/AKT and MAPK pathways.

The pharmacokinetic properties of methyl 2-methanesulfonyl-6-oxo-1,2-diazinane-4-carboxylate have been extensively studied to evaluate its suitability for therapeutic use. Research has shown that this compound exhibits favorable oral bioavailability and a reasonable half-life, which are crucial parameters for drug development. Furthermore, it has been found to have low toxicity in animal models, suggesting a favorable safety profile.

The synthesis of methyl 2-methanesulfonyl-6-oxo-1,2-diazinane-4-carboxylate involves several well-established chemical reactions. One common synthetic route starts with the formation of a diazinane ring through a cyclization reaction followed by the introduction of the methanesulfonyl group via sulfonylation. The carboxylate ester is then introduced through esterification or transesterification reactions. These synthetic steps can be optimized to achieve high yields and purity levels, making large-scale production feasible.

In conclusion, methyl 2-methanesulfonyl-6-oxo-1,2-diazinane-4-carboxylate (CAS No. 339096-89-8) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in the pharmaceutical industry. Ongoing studies are expected to uncover additional therapeutic benefits and optimize its use in clinical settings.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)